Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Abnormal plasma Aβ42/40 ratio identified older adult groups with lower memory scores, higher dementia risks, and higher ADRD biomarker levels, with potential implications for population screening.
-
55/100
Elaborating on the results, we validated one finding using a quantitative assessment of TDP-43 pathology in the granular layer of the hippocampus in FTLD-TDP brain donors with (n = 15) and without (n = 15) hallucinations.
-
55/100
TDP-43 was significantly elevated in plasma ADEVs derived from autopsy confirmed LATE-NC subjects, with or without comorbid AD pathology.
-
Both plasma and CSF measures of Aβ42/Aβ40 and NfL predicted cognitive decline.
-
Serum beta-synuclein changes differ from those of NfL and p-tau181 and are strongly related to AD, most likely reflecting temporal synaptic degeneration.
-
Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer's disease (AD) patients.
-
Baseline plasma NfL was a significant predictor of psychotic symptoms longitudinally across the study adjusted for age, Hoehn and Yahr stage, duration of follow up, duration of disease, baseline levodopa and dopamine agonist medication, and baseline cognition: (OR 8.15 [95% CI 1.40–47.4], p = 0.020).
-
In total, samples from 610 individuals from four clinical centres were investigated in this study.
-
Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging systems.
-
GFAP may be an early AD biomarker increasing before p-tau181 and NfL and the effect modifying role of cardiovascular health should be considered in biomarker risk stratification.
-
Plasma p-tau231 showed more robust associations with PET biomarkers than p-tau181 in presymptomatic individuals.
-
Significantly stronger between-tracer correlations (P < .001) were observed after harmonization for both global amyloid burden indices and voxel-wise measurements in the training cohort and the external testing cohort.
-
Increasing variation greatly impacted the performance of plasma Aβ42/40 in discriminating Aβ status.
-
Neurodegenerative biomarkers were elevated to levels observed in AD dementia and associated with encephalopathy and worse outcomes among hospitalized COVID-19 patients.
-
Plasma phosphorylated tau species have been recently proposed as peripheral markers of Alzheimer's disease (AD) pathology.
-
AUC-based performance was similarly good for the pTau181/Aβ42 ratio (AUC=0.841; 95% CI: 0.759-0.923), pTau181/Aβ40 ratio (AUC=0.837; 95% CI: 0.754-0.919), Aβ42/Aβ40 ratio (AUC=0.829; 95% CI: 0.746-0.912), tTau/Aβ42 ratio (AUC=0.822; 95% CI: 0.736-0.908), pTau181/Aβ42/Aβ40 ratio (AUC=0.817; 95% CI: 0.734-0.901), and Aβ42 (AUC=0.812; 95% CI: 0.722-0.902).
-
Plasma NfL is a useful prognostic biomarker for PD, predicting clinical conversion to mild cognitive impairment or dementia. © 2021 International Parkinson and Movement Disorder Society.
-
A non-invasive and sensitive blood test has long been a goal for early stage disease diagnosis and treatment for Alzheimer's disease (AD) and other proteinopathy diseases.
-
Plasma tau phosphorylated at threonine 181 (p-tau181) predicts Alzheimer's disease (AD) pathology with high accuracy in the general population.
-
Plasma p-tau181 had correlations with broader cognitive domains, suggesting its potential as a promising clinical-relevant blood-based biomarker.
-
These data suggest that p-tau/Aβ42 and Aβ42/40 ratios provide similar clinical information in the assessment of amyloid pathology.
-
Compared to Simoa biomarkers, APEX-Aβ42 showed significantly higher correlations with amyloid PET retention values and excellent diagnostic performance (sensitivity 100%, specificity 93.3%, area under the curve 0.995).
-
The NTK contains promising markers that improve the pathophysiological characterization of AD.
-
Plasma phospho-tau217 correlated with plasma phospho-tau181, CSF phospho-tau217 (rs = 0.68, P < 0.001), and negatively with CSF β-amyloid42/40 (rs = -0.52, P = 0.001).
-
The CSF α-synuclein levels correlated with AD-specific biomarkers, CSF total tau and phosphorylated tau levels, in 651 Chinese Han participants (training set).
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Subthreshold Amyloid Predicts Tau Deposition in Aging
- Flortaucipir tau PET imaging in semantic variant primary progressive aphasia
- Spectral-Domain OCT Measurements in Alzheimer's Disease: A Systematic Review and Meta-analysis
- Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences
- Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance
- Distinct cerebrovascular pathways underlying Alzheimer's disease-related neurodegeneration
- Recent diagnostic techniques for the detection of Alzheimer's disease: a short review
- Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease
- Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population
- Upregulation of endocytic protein expression in the Alzheimer's disease male human brain